Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65.8M
-
Number of holders
-
170
-
Total 13F shares, excl. options
-
46.3M
-
Shares change
-
+2.82M
-
Total reported value, excl. options
-
$1.79B
-
Value change
-
+$97.4M
-
Put/Call ratio
-
0.44
-
Number of buys
-
87
-
Number of sells
-
-69
-
Price
-
$38.64
Significant Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q4 2021
214 filings reported holding CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $.001 as of Q4 2021.
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) has 170 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 46.3M shares
of 65.8M outstanding shares and own 70.39% of the company stock.
Largest 10 shareholders include FMR LLC (7M shares), RTW INVESTMENTS, LP (3.92M shares), BlackRock Inc. (3.1M shares), VANGUARD GROUP INC (2.41M shares), STATE STREET CORP (2.37M shares), WELLINGTON MANAGEMENT GROUP LLP (2.19M shares), Redmile Group, LLC (2.17M shares), RA CAPITAL MANAGEMENT, L.P. (1.8M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.24M shares), and CITADEL ADVISORS LLC (1.07M shares).
This table shows the top 170 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.